IP Library › Granted Patent US 12,442,015
Granted Patent B2
US 12,442,015 · App. 16/962,005 · Granted Oct 14, 2025

Closed-ended DNA vectors obtainable from cell-free synthesis and process for obtaining ceDNA vectors

Inventors: Ozan Alkan (Cambridge, MA); Robert Michael Kotin (Cambridge, MA); Matthew Stanton (Cambridge, MA); Douglas Anthony Kerr (Cambridge, MA); Carolyn Pelletier (Cambridge, MA)
Assignee: Generation Bio Co.
C12N15/85C12N2800/105
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,442,015
App. No.
16/962,005
Granted
Oct 14, 2025
Kind
B2
Abstract

The application describes methods for synthetic synthesis and cell-free synthesis of DNA vectors, particularly closed-ended DNA vectors (e.g., ceDNA vectors) having linear and continuous structure for delivery and expression of a transgene. The present invention relates to an in vitro process for production of closed-ended DNA vectors, corresponding DNA vector products produced by the methods and uses thereof, and oligonucleotides and kits useful in the process of the invention. DNA vectors produced using the methods described herein are free from unwanted side effects due to contaminants introduced during production in cell lines, for example, bacterial or insect cell lines. Further provided herein are methods and cell lines for reliable gene expression in vitro, ex vivo and in vivo using the ceDNA vectors synthesized using the methods herein.

Claims (24)

1. A cell-free method of preparing a non-viral, linear and closed-ended DNA (ceDNA) vector comprising:

providing a first single-stranded inverted terminal repeat (ITR) molecule comprising a first ITR;

providing a second single-stranded ITR molecule comprising a second ITR, wherein the first ITR and the second ITR are synthetic;

providing a double-stranded polynucleotide comprising a double-stranded expression cassette sequence, wherein the double-stranded polynucleotide comprising the double-stranded expression cassette is obtained by excision from a double-stranded DNA construct; and

ligating the 5′ and 3′ ends of the first ITR molecule to a first end of the double-stranded polynucleotide and ligating the 5′ and 3′ ends of the second ITR molecule to a second end of the double-stranded polynucleotide to form the ceDNA vector, wherein:

the first ITR molecule comprises a first overhang region that is complementary to an overhang region on the first end of the double-stranded polynucleotide, and the second ITR molecule comprises a second overhang region that is complementary to an overhang region on the second end of the double-stranded polynucleotide;

each of the first overhang region and the second overhang region is located in an A-stem of the respective ITR; and

ITR D regions are present in the double-stranded expression cassette sequence;

thereby preparing the ceDNA vector without using cells.

2. The method of claim 1 , further comprising a step of synthesizing at least one of the first ITR and the second ITR using in vitro DNA synthesis prior to the providing steps.

3. The method of claim 1 , wherein, within the double-stranded DNA construct, the double-stranded polynucleotide comprising the double-stranded expression cassette sequence is flanked at the 5′ end by a first restriction endonuclease cleavage site and at the 3′ end by a second restriction endonuclease cleavage site.

4. The method of claim 1 , wherein the double-stranded DNA construct is selected from the group consisting of: a bacmid, a plasmid, a minicircle, and a linear double-stranded DNA molecule.

5. The method of claim 1 , wherein at least one of the first ITR and the second ITR are annealed prior to ligation to the double-stranded polynucleotide comprising the expression cassette sequence.

6. The method of claim 1 , wherein the ligation is effected by T4 ligase or an AAV Rep protein.

7. The method of claim 1 , wherein the first ITR is selected from the group consisting of a wild-type ITR and a modified ITR, and/or the second ITR is selected from the group consisting of a wild-type ITR and a modified ITR.

8. The method of claim 1 , wherein at least one of the first ITR and the second ITR comprises at least one RBE site.

9. The method of claim 1 , wherein at least one of the first ITR and the second ITR is an AAV ITR or an AAV-derived ITR.

10. The method of claim 1 , wherein the double-stranded expression cassette sequence comprises at least one cis-regulatory element.

11. The method of claim 1 , wherein the double-stranded expression cassette sequence comprises a transgene sequence.

12. The method of claim 11 , wherein the transgene sequence encodes a protein.

13. The method of claim 1 , wherein the double stranded polynucleotide comprises at least one RBE element and an ITR D region.

14. The method of claim 1 , wherein the method steps are all performed in a manner that does not involve replication of the ceDNA vector by or inside of a cell or using a cellular extract.

15. The method of claim 1 , wherein the double-stranded polynucleotide comprises a first Rep binding element (RBE) and a second RBE.

16. The method of claim 1 , wherein each of the first overhang region and the second overhang region is located in the A-stem of the respective ITR between: hairpin loop sequences B and C, and a Rep binding element (RBE).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2021
From: ALKAN, OZAN; KOTIN, ROBERT MICHAEL; STANTON, MATTHEW G.; KERR, DOUGLAS ANTHONY; PELLETIER, CAROLYN
To: GENERATION BIO CO.
Reel/Frame 056531/0587 →
Continuity (2)
Provisional Application 62619392 · Jan 19, 2018
Related Publication 20210071197A1 · Mar 11, 2021
References Cited (26)
US 11066679B2 · Kotin · 2021 [cited by examiner]
US 20020164783A1 · Feldhaus · 2002 [cited by applicant]
US 20030211103A1 · Buyse et al. · 2003 [cited by applicant]
US 20090117615A1 · Banzai et al. · 2009 [cited by applicant]
US 20100105110A1 · Danthinne · 2010 [cited by examiner]
US 20140107186A1 · Garcia et al. · 2014 [cited by applicant]
US 20140271551A1 · Hirsch et al. · 2014 [cited by applicant]
US 20190032083A1 · Kotin · 2019 [cited by examiner]
US 20220119840A1 · Kerr · 2022 [cited by examiner]
US 20220195456A9 · Kotin · 2022 [cited by examiner]
US 20220228171A1 · Alkan · 2022 [cited by examiner]
JP 2010046066A · 2010 [cited by applicant]
WO 1993009239A1 · 1993 [cited by applicant]
WO 2017152149A1 · 2017 [cited by applicant]
WO 2019101596A1 · 2019 [cited by applicant]
WO 2019161059A1 · 2019 [cited by applicant]
WO 2021011842A1 · 2021 [cited by applicant]
Nahreini et al., Cloning and integration of DNA fragments in human cells via the inverted terminal repeats of the adeno-associated virus 2 genome. Gene. Oct. 1, 1992;119(2):265-72. [cited by applicant]
Dennis. Welfare issues of genetically modified animals. ILAR J. 2002;43(2):100-9. [cited by applicant]
Maksimenko et al., Cyclic oligonucleotides. II. Regularities in the formation of polycyclic structures. Bioorg Khim. Feb. 1997;23(2):127-33. [cited by applicant]
Muller et al., Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial. Arthritis Rheum. Dec. 2008;58(12):3873-83. [cited by applicant]
Xu et al., Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics. J Pharm Sci. Jan. 2011;100(1):38-52. [cited by applicant]
Zhou et al., Developing tTA transgenic rats for inducible and reversible gene expression. Int J Biol Sci. 2009;5(2):171-81. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2019/014122, dated Apr. 11, 2019, 14 pages. [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2019/014122, dated Jul. 30, 2020, 11 pages. [cited by applicant]
Cataldi et al., Hairpin-end conformation of adeno-associated virus genome determines interactions with DNA-repair pathways. Gene Ther. Jun. 2013;20(6):686-93. [cited by applicant]